首页> 外文期刊>Expert opinion on pharmacotherapy >Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid
【24h】

Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid

机译:Loteprednol Etabonate用于眼前段的炎症状况:二十年的临床经验,左右设计的皮质类固醇

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Topical corticosteroids are an important pharmacotherapy for the management of various inflammatory conditions affecting the anterior segment of the eye. However, medications in this class are associated with well-known risks including increased intraocular pressure (IOP) and development of cataracts. The topical corticosteroid loteprednol etabonate (LE) was developed with the specific intention of minimizing these side effects.
机译:简介:局部皮质类固醇是一种重要的药物治疗,用于管理影响眼睛前段的各种炎症病症。 然而,该类的药物与众所周知的风险相关,包括增加的眼内压(IOP)和白内障的发育。 局部皮质类固醇蛋白酶蛋白酶酸替氏肾上腺素(LE)具有最小化这些副作用的具体意图。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号